Subcutaneous injection formulation for reducing body weight and uses thereof

Abstract

The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

1 - 30 . (canceled) 
     
     
         31 . A method of reducing the body weight of an overweight human or an obese human in need thereof, consisting essentially of administering a therapeutically effective amount of a subcutaneous injection formulation to the overweight human or obese human, wherein the subcutaneous injection formulation consists essentially of:
 a) a curcuminoid; and   b) polyoxyl-35 castor oil, PEG-40 hydrogenated castor oil or 2-hydroxyethyl 12-hydroxyoctadecanoate;   wherein the polyoxyl-35 castor oil, PEG-40 hydrogenated castor oil or 2-hydroxyethyl 12-hydroxyoctadecanoate and the curcuminoid form a plurality of curcuminoid-containing micelles, which encapsulate the curcuminoid;   wherein a total concentration of the curcuminoid in the curcuminoid-containing micelles is 0.2 to 167 mg/g;   wherein the weight ratio of the curcuminoid to the polyoxyl-35 castor oil, PEG-40 hydrogenated castor oil or 2-hydroxyethyl 12-hydroxyoctadecanoate is 1:20 to 1:150; and   wherein the body weight of the overweight human or the obese human in need thereof is effectively reduced.   
     
     
         32 . The method of  claim 31 , wherein the curcuminoid is curcumin. 
     
     
         33 . The method of  claim 32 , wherein the total concentration of the curcuminoid in the curcuminoid-containing micelles is 0.4 to 167 mg/g. 
     
     
         34 . The method of  claim 32 , wherein the total concentration of the curcuminoid in the curcuminoid-containing micelles is 0.5 to 111 mg/g. 
     
     
         35 . The method of  claim 32 , wherein the total concentration of the curcuminoid in the curcuminoid-containing micelles is 2 to 91 mg/g. 
     
     
         36 . The method of  claim 32 , wherein the subcutaneous injection formulation further consists essentially of a catechin. 
     
     
         37 . The method of  claim 36 , wherein the concentration of the catechin is 0.04 to 835 mg/g. 
     
     
         38 . The method of  claim 37 , wherein the concentration of the catechins is 0.15 to 733 mg/g. 
     
     
         39 . The method of  claim 36 , wherein the catechin is selected from the group consisting of epigallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin, gallocatechin gallate, gallocatechin, catechin gallate, and a combination thereof. 
     
     
         40 . The method of  claim 33 , wherein the weight ratio of the curcuminoid to the catechin in the subcutaneous injection formulation is 50:1 to 1:20. 
     
     
         41 . The method of  claim 40 , wherein the weight ratio of the curcuminoid to the catechin in the subcutaneous injection formulation is 30:1 to 1:10. 
     
     
         42 . The method of  claim 41 , wherein the weight ratio of the curcuminoid to the catechins in the subcutaneous injection formulation is 10:1 to 1:4. 
     
     
         43 . The method of  claim 41 , wherein the weight ratio of the curcuminoid to the catechins in the subcutaneous injection formulation is 7:1 to 1:4. 
     
     
         44 . The method of  claim 32 , wherein the therapeutically effective amount of the subcutaneous injection formulation is 0.15 to 40 milligram per kilogram for injection into the human in need thereof. 
     
     
         45 . The method of  claim 44 , wherein the therapeutically effective amount of the subcutaneous injection formulation is 0.25 to 25 milligram per kilogram for injection into the human in need thereof. 
     
     
         46 . The method of  claim 32 , wherein the administration frequency of the subcutaneous injection formulation at an administration site of the human in need thereof is 1 to 6 times every 1 to 90 days. 
     
     
         47 . The method of  claim 32 , wherein the subcutaneous injection formulation further consists essentially of:
 a) a cosolvent selected from the group consisting of polyethylene, glycol, propylene glycol, and ethanol;   b) a suspending agent selected from the group consisting of sodium alginate, glycerol, carboxymethylcellulose sodium, and mannitol; and   c) an oil phase excipient selected from the group consisting of oleic acid, castor oil, sesame oil, cottonseed oil, soybean oil, safflower oil, corn oil, glycerol, and   a combination thereof.   
     
     
         48 . The method of  claim 47 , wherein the subcutaneous injection formulation further consists essentially of the cosolvent, the oil phase excipient, the suspending agent, or a combination thereof. 
     
     
         49 . The method of  claim 32 , wherein the subcutaneous injection formulation further consists essentially of resveratrol, wherein the polyoxyl-35 castor oil, PEG-40 hydrogenated castor oil or 2-hydroxyethyl 12-hydroxyoctadecanoate and the resveratrol form a plurality of resveratrol-containing micelles, which encapsulate the resveratrol. 
     
     
         50 . The method of  claim 49 , wherein the total concentration of the resveratrol encapsulated in the resveratrol-containing micelles is 0.2 to 733 mg/g. 
     
     
         51 . The method of  claim 49 , wherein the total concentration of the curcuminoid encapsulated in the curcuminoid-containing micelles and of the resveratrol encapsulated in the resveratrol-containing micelles is 0.4 to 900 mg/g. 
     
     
         52 . The method of  claim 49 , wherein the ratio of the total weight of the curcuminoid encapsulated in the curcuminoid-containing micelles to the total weight of the resveratrol encapsulated in the resveratrol-containing micelles is 50:1 to 1:30. 
     
     
         53 . The method of  claim 52 , wherein the ratio of the total weight of the curcuminoid encapsulated in the curcuminoid-containing micelles to the total weight of the resveratrol encapsulated in the resveratrol-containing micelles is 20:1 to 1:20.